Yellow fever vaccine safety: A reality or a myth?

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3627-3628

  Arya, Subhash C ^a  

^a Centre for Logistical Research and Innovation India   (India)

Author keywords

17D yellow fever vaccine; Magnetic resonance imaging; Neurovirulence; Viscerotropism

Indexed keywords

YELLOW FEVER VACCINE;

ARTICLE; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; HAMSTER; HISTOPATHOLOGY; HUMAN; IMMUNIZATION; MULTIPLE ORGAN FAILURE; NEUROTROPISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMATE; PRIORITY JOURNAL; SURVIVAL; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ANIMAL; DISEASE MODEL; IMMUNOLOGY; PROSPECTIVE STUDY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PROSPECTIVE STUDIES; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 0036839931     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00409-7     Document Type: Note

References (12)

1. Receveur M.C., Thiebaut R., Vedy S., Malvy D., Mercie P., Bras M.L. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin. Infect. Dis. 31(3):2000;E7-8.
2. Mariannea P., Georìes-Cambot M.-C., Deubel V. Rarity of adverse effects of 17D yellow-fever vaccination. Lancet. 358:2001;84-85.
3. WHO Expert Committee on Biological Standardization. Requirements for yellow fever vaccine (46th Report). WHO Tech. Rep. Ser. 1998;872:30-68.
4. Ozawa H., Noma S., Yoshida Y., Sekine H., Hashimoto T. Acute disseminated encephalomyelitis associated with poliomyelitis vaccine. Pediatr. Neurol. 23:2000;177-179.
5. Forton D.M., Allsop J.M., Main J.et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 358:2001;38-39.
6. Lovenbook I.S., Pellen L.J., Elisberg B.L. The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J. Biol. Standardization. 15:1987;305-313.
7. Tesh R.B., Guzman H., Travaasss de Rosa A.P.A.et al. Experimental yellow fever infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 183:2001;1431-1436.
8. Xio S.-Y., Zhang H., Guzman H., Tesh R.B. Experimental yellow fever infection in the golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 183:2001;1437-1444.
9. Notice to readers: fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR 2001;50(30):643-5.
10. Adu F.D., Adedeji A.A., Esan J.S., Odusanya O.G. Live viral vaccine potency: an index for assessing the cold chain system. Public Health. 110:1996;325-330.
11. Verheyden B., Andrus K., Rombart B. Capsid and RNA stabilization of the oral poliovaccine. Vaccine. 19:2001;1899-1905.
12. Martin M., Weld L.H., Tsai T.F.et al. Advanced age as a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis. 7(6):2001;945-951.